Genomind Press

Leading Healthcare Executives Join Genomind To Advance Personalized Medicine In Psychiatry

August 9, 2011 – Chalfont, Pennsylvania – Genomind, LLC, a company focused on neuropsychiatric personalized medicine, announced key additions to its executive team. Joining the company are Scott A. Storrer, former Group President of Cardinal Health’s pharmaceutical business, as Chief Operating Officer; Michael Koffler, who served as an investment banker with Rothschild, Inc., as Chief Financial Officer; Daniel Giacomelli, who was a Senior Project/Program Manager at CIGNA Healthcare and Group Insurance, as Chief Information Officer; and Bryce Kasuba, prior Director of Clinical Operations at Concordant Rater Systems (CRS), as Vice President of Clinical Operations.

“We are gratified by the commitment shown by these talented healthcare and medical technology executives in joining Genomind’s effort to improve treatment options for prescribing clinicians through personalized medicine,” said Ronald I. Dozoretz, MD, Chairman and CEO of Genomind. “Along with Genomind’s influential Scientific Advisory Board, our executive team is dedicated to advancing the use of biomarker testing to help care for patients suffering from mental illness.”

The Genomind executive team currently includes Dr. Dozoretz, founder of ValueOptions and a recognized national leader and advocate for behavioral health quality, access, and innovation; Jay Lombard, DO, Chief Scientific Officer and Medical Director, who served as Chief of Neurology and head of the Stroke Department at Bronx Lebanon Hospital and a noted expert on neuropsychiatry practice and research; Stanley Frank, Ed. D., Vice Chairman, who led CBS Publishing Group as its President; and Nancy L. Grden, General Manager, former Chief Marketing Officer for Amerigroup and ValueOptions.

Scott A. Storrer – Chief Operating Officer

A 20-year healthcare industry veteran, Mr. Storrer completed the business turnaround of MEDecision, a leading health information technology company, where he held the position of President & Chief Executive Officer. Mr. Storrer has held positions with Cardinal Health, where he was Group President of Cardinal’s $81 billion pharmaceutical segment and CIGNA Corporation, serving as Executive Vice President, Service and Information Technology. His background also includes executive management positions with Liberty Mutual Group and GE’s financial management program. Mr. Storrer holds a BA in Economics and Mathematics from DePauw University, an MBA from Boston University, and has completed executive training at Harvard University.

Michael Koffler – Chief Financial Officer

Prior to joining Genomind, Mr. Koffler was a Vice President at Versa Capital Management where he focused on investing in and working with companies undergoing turnarounds. In addition to executing transactions, Mr. Koffler worked with his portfolio companies to formulate and implement strategic plans, general business improvement projects, budgets and cash forecasts. Mr. Koffler began his career as an investment banker with Wasserstein Perella & Co. and later with Rothschild, Inc. As an investment banker, he focused on corporate restructurings, mergers and acquisitions and raising capital. Mr. Koffler received a BBA in Finance from the George Washington University and an MBA from Harvard Business School.

Daniel Giacomelli – Chief Information Officer

Mr. Giacomelli has over 17 years of experience in consulting and project/program management, process engineering, solutions and operations management. Prior to joining Genomind, Mr. Giacomelli was a Senior Project/Program Manager within CIGNA Healthcare and Group Insurance responsible for implementing high profile projects and an integral part of the Program Management Office and Segment Leadership teams. Mr. Giacomelli was also the Solutions Architect for Canon Technology Solutions, specializing in Solutions Architecture, Web Analytics, Microsoft Solutions, Governance and Strategic Advisory services, and Project/Program Management. Mr. Giacomelli also acquired extensive management and technical consulting experience during his time at Computer Sciences Corporation and CDI Corporation for Fortune 500 companies as a Principal Consultant. Mr. Giacomelli received his B.S. in Operations Management from West Virginia University.

Bryce Kasuba – Vice President, Clinical Operations

Mr. Kasuba has spent his career working on innovative research and treatments in psychiatry. Prior to joining Genomind, he was the Director of Clinical Operations at Concordant Rater Systems (CRS), a rater training and monitoring company acquired by Medco. Mr. Kasuba has worked on many Major Depression and Bipolar studies and managed a global Phase 3 Bipolar Depression study of adjunctive Geodon at Pfizer. At AstraZeneca, he was a part of the Seroquel team and assisted in the Investigator Sponsored Studies program. Mr. Kasuba is a graduate of University of the Sciences with an MBA in Pharmaceutical Business. He has an MA in Counseling from Fairfield University and is a Licensed Professional Counselor and a Licensed Drug and Alcohol Counselor. He began his career at Yale conducting research on Motivational Enhancement Therapy for schizophrenia and cocaine sponsored by NIDA. He has a BA in Communications from La Salle University.

About Genomind, LLC

Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of personalized medicine into psychiatry by providing genetic information to better understand the patient. Genomind was founded by Ronald I Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health and bringing innovations in science, delivery, and access to mental health patients. He also is founder of ValueOptions, one of the nation’s leading behavioral health and wellness companies. Dr Lombard, a neurologist, is co-founder of Genomind and is a nationally recognized leader in neuropsychiatry practice, research, and thought leadership. Learn more at

"*" indicates required fields

This field is for validation purposes and should be left unchanged.